Paper Details

  1. Home
  2. Paper Details

Effects of rasagiline on the progression of nonmotor scores of the MDS-UPDRS.

Author: , HauserRobert A, LangAnthony, PoeweWerner

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Rasagiline 1 mg/day was associated with significantly less decline in nonmotor experiences of daily living compared to placebo in early Parkinson's disease (PD) patients.
Paper Details　
Original Abstract of the Article :
BACKGROUND: A draft version of part 1 (Non-Motor Aspects of Experiences of Daily Living; nM-EDL) of the MDS-UPDRS scale was employed as a secondary outcome in the ADAGIO study, which assessed the effect of rasagiline in early Parkinson's disease (PD) patients. METHODS: This analysis includes 1,150 ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/mds.26124

データ提供：米国国立医学図書館（NLM）

Rasagiline: A Potential Ally in the Fight Against Parkinson's Disease

The journey through Parkinson's disease can be arduous, my friends. It's like traversing a desert, facing the challenges of motor and non-motor symptoms. This study focuses on rasagiline, a drug that has shown promise in the treatment of Parkinson's disease. The researchers delved into the effects of rasagiline on the progression of non-motor scores in patients with early-stage Parkinson's disease. They utilized data from the ADAGIO study, a comprehensive research project investigating the efficacy of rasagiline. The researchers carefully analyzed data from 1,150 individuals with Parkinson's disease who were randomly assigned to receive either placebo or rasagiline for 36 weeks.

Rasagiline: A Potential Slowdown in Non-Motor Deterioration

The researchers observed a significant deterioration in non-motor scores from baseline in the placebo group, while the rasagiline group exhibited significantly less deterioration. This suggests that rasagiline might have a beneficial effect in slowing the progression of non-motor symptoms in individuals with Parkinson's disease. It's like a caravan finding a sturdy camel, providing support and resilience during the journey through a challenging landscape.

A Promising Step Forward

While the clinical implications of these findings remain to be fully explored, this study offers a glimmer of hope for those living with Parkinson's disease. It suggests that rasagiline may be a valuable tool in mitigating the impact of non-motor symptoms. It's like discovering a hidden oasis, offering respite and relief from the harsh realities of the disease.

Dr.Camel's Conclusion

This study provides valuable insights into the potential benefits of rasagiline in managing non-motor symptoms associated with Parkinson's disease. While further research is needed to fully understand its long-term effects, this study offers a promising avenue for exploring new treatment strategies and improving the lives of individuals living with this challenging condition.

Date :
  1. Date Completed 2015-12-21
  2. Date Revised 2022-03-30
Further Info :

Pubmed ID

25545629

DOI: Digital Object Identifier

10.1002/mds.26124

Related Literature

Article Analysis
・Effects of rasagiline
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.